The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

An influencer who was left looking “like an alien” after an adverse reaction to dermal fillers triggered a skin condition has ...

An influencer who experienced a severe reaction to dermal fillers, resulting in a psoriasis diagnosis, has discovered a ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

It is more common in teenagers and young adults ... It May Heal Scalp Conditions In a study examining turmeric's effect on one skin condition, scalp psoriasis, 40 patients were divided into two groups ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...

In clinical trials, roflumilast foam has shown strong potential in reducing psoriasis symptoms on both the scalp and body. Though, in this study, researchers explored roflumilast foam’s safety and ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

But a biopsy is sometimes needed for confirmation. Psoriasis can also develop on the nails or on the scalp. Most people have just one kind of psoriasis, but you can develop a new subtype of the ...